Nitromed (NTMD) Inactive 10-K2008 FY Annual report

Filed: 19 Mar 09, 12:00am

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigious
Readability	H.S. freshman Avg

New words: accuracy, affiliate, affiliated, al, Archemix, attestation, bate, bore, borne, cancelled, christopher, clarified, cohen, complaint, corroborated, counterparty, County, Cubist, curable, decree, Deerfield, discharge, dissolution, dissolve, domestic, duly, energy, entitled, entry, Ernst, eventual, eventually, extraordinary, fiduciary, FSP, horizon, identical, illegal, inaccuracy, interrupt, interrupted, Jane, JHP, jurisdiction, kenneth, Kramer, littlechild, LLP, lowest, maximum, Mieczyslaw, minimal, minimize, multiplied, nonappealable, observable, omitted, ordinary, page, Parent, pendency, plant, Postemployment, preceding, purported, purpose, qualification, recessionary, recurring, refine, reinstated, reinstatement, relief, requisite, rescissory, resume, resumption, Retention, sobecki, Stachnik, student, Suffolk, thereto, undersigned, unfair, unobservable, vigorously, waiver, Young

Removed: accommodate, account, acute, add, amortized, Angiogenix, Astra, attract, Australian, awarded, back, bank, bear, biochemical, biological, BIOTECH, Canadian, cellular, central, chattel, chemically, clause, commitment, construed, Cooperation, created, damage, damaged, delivered, dependent, deposit, developmental, device, duration, dysfunction, elevated, enhanced, enhancing, enroll, EP, EPO, escrow, extension, feature, fever, Furchgott, gain, gastrointestinal, GmbH, goal, harmful, healing, important, ineffective, inflammation, inflammatory, inorganic, interact, internally, invest, linked, Master, member, mitigated, moiety, NicOx, nitrate, Nobel, operate, opposition, organic, overlap, pain, PCT, physiological, Physiology, pivotal, polymer, Prize, profitably, rapidly, realize, regular, releasing, renal, rendered, RenoPharm, rental, repay, reputational, respiratory, retirement, revoke, scientifically, sexual, short, strategy, surface, thereon, timetable, toxicity, Treaty, understood, unilateral, unproven, unqualified, vascular, Vasopharm, vessel, working, wound, Zeneca

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Related press release

NTMD similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

EXHIBIT 32.1

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Annual Report on Form 10-K of NitroMed, Inc. (the “Company”) for the fiscal year ended December 31, 2008 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), the undersigned, Kenneth M. Bate, President, Chief Executive Officer and Interim Chief Financial Officer of the Company, hereby certifies, pursuant to 18 U.S.C. Section 1350, that:

(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Dated: March 19, 2009	/s/ Kenneth M. Bate
	Kenneth M. Bate
	President, Chief Executive Officer and Interim Chief Financial Officer (Principal Executive Officer and Principal Financial Officer)